

Sunday May 10, 2009

Morning

PL 1 Drug Transporters in the New Drug Discovery and Development [Y Sugiyama]

**S1 : Transporters as Useful Targets for Drug Discovery and Development [KI Inui/V Chatsudthipong]**

1. Renal Organic Cation Transporter, OCT & MATE – From Drug Discovery to Clinical Applications [KI Inui]
2. The Organic Anion Transporters : Impact on Efficacy and Targeting of Drugs [JB Pritchard]
3. Role of Intestinal and Hepatic OATPs (Organic Anion Transporting Polypeptides) in Drug Absorption and Disposition [I Tamai]
4. Natural Plant-Derived Compounds Interact with Membrane Transporters and Channels Role of Human Copper Transporter hCtr1 in Cisplatin Resistance [V Chatsudthipong]
5. Role of Human Copper Transporter hCtr1 in Cisplatin Resistance [IS Song]

**S2 : Genome-Based Technology for Drug Toxicity Assessment [AK Giri/M Chulasiri]**

1. Proteomics Approach to Find Biomarkers for Genotoxicity [T Suzuki]
2. Molecular and Genomic Approach for Understanding the Toxicological Mechanisms of ROS-inducing Agents in Human Cells using Three-Dimensional (3D) Cell Culture System [YR Seo]
3. Genomic approaches to identify arsenic toxicity [AK Giri]
4. Nutrigenomic Analysis of Diet-Gene Interactions on Functional Supplements for Weight Management [D Bagchi]

Sunday May 10, 2009

Afternoon

**S3 : Novel Strategies for the Discovery and Development of Safer Drugs [CY Zong/B Ongpipattanakul]**

1. Developing Virtual Screening and Toxicity Prediction Tools by Using Machine Learning Methods [YZ Chen]
2. Stryllactones – Current Status and Future Prospects for Drug Development [IH Salmaan]
3. From Barakol Experiences to Novel Strategies of Safer Drugs [P Pramyothin]
4. Vanilloid receptor 1 (VR1) ligands as the next generation of analgesic for neuropathic pain [J Lee]

**S4 : The Exposure, Metabolism and Health Effects of Arsenic [K Kitchin/P Sinhaseni]**

1. Identification and quantification of arsenic metabolites in exposure, metabolism, and health effects studies [B Adair]
2. Role of Transporters in Arsenic Disposition and Accumulation [JD Huang]
3. The Mode of Action of arsenic – binding and oxidative stress [K Kitchin]
4. Arsenic and Immune System [Satayavivad]
5. Arsenic Poisoning & Bangladesh Children [Q. Quamruzzaman]

Monday May 11, 2009

Morning

PL 2 UDP-Glucuronosyltransferase and Drug Glucuronidation-Linking Structure, Function and Kinetics [J Miners]

**S5 : Drug Metabolizing Enzymes for Activation and Detoxification of Xenobiotics**  
[Y Yamazoe/ W Tassaneeyakul]

1. Toxicogenetic Approach to Understand Chemical-Induced Liver Toxicity  
[Y Yamazoe]
2. Metabolic Activation of Capsaicin and Inhibition of NADPH - Quinone Oxidoreductase : Overproductin of ROS byt Capsaicin Induces Adaptive Upregulation of Heme Oxygenase-1 and Provides Cytoprotection  
[YN Cha]
3. UGT Enzymes : Drug Interactions, Protein-Protein Interaction and Regulation  
[T Yokoi]
4. Drug Metabolizing Enzymes in Thalassemia Patients  
[V Kukongviriyapan]

**S6 : Dietary Modulation of Xenobiotics Transport and Metabolism**  
[YJ Surh/M Suttajit]

1. Environmental and dietary modulations of intestinal transporter function  
[E Lee]
2. Induction of antioxidant and detoxifying enzymes by dietary phytochemicals  
[YJ Surh]
3. Modulation of 5-alpha-reductase and aromatase activities in prostate carcinogenesis  
[JK Lin]
4. Chemicals and Biomodifiers to Prevent Cancer and Malformation  
[T Nomura]

Monday May 11, 2009

Afternoon

**S7 : Transcription Factors and Their Regulators Modulated by Xenobiotics**  
[P Macenzie/ K Yoovathaworn]

1. Transcriptional Control of UDP Glucuronosyltransferases  
[P Macenzie]
2. Flavin –containing Monooxygenase 3 (FMO3) Expressions in Human Livers Associated with HNF-4 and NF-Y  
[H Yamazaki]
3. Novel Transcriptional Activation of the CYP3A4 Gene  
[K Nagata]
4. Inter-individual Variation of Transcription Factors Regulating DMPK Genes  
[SS Lee]

**S8 : Oxidative Stress and Inflammation : Mechanisms and Treatments**  
[K Knight/ P Akaraserinont]

1. Non-steroidal Anti-inflammatory Drugs and the Advancing Tide of Toxicity  
[K Knight]
2. Non-Steroidal Anti-inflammatory Drugs : Present and Future  
[P Akaraserinont]
3. Phytochemical Regulation of Phase II and III Enzymes : Protective Roles in Oxidative Stress and Inflammation  
[SG Kim]
4. Oxidative Stress & Inflammation: Potential Drug Target for Diabetic Complications  
[K Chopra]
5. Evaluation of Anti-inflammatory Agents from Natural Origin : Problem of Efficacy Study  
[K Yoovathaworn]

Tuesday May 12, 2009  
Morning

PL 3 Discovery of Biomarkers for Gene Expression and Drug Toxicity and Efficacy [F Gonzalez]

**S9 : Promise of Pharmacogenomics in the Era of Personalized Drug Therapy**  
[H Zhou/T Sura]

1. Experience with Cytochrome P450 2D6 Genotype in Thai Population Jigsaw in Array-based Genotyping  
[C Limwongse]
2. Pharmacogenomics in the Treatment of Thalassemia  
[T Sura]
3. Pharmacogenetics of beta blockers: ethnicity, genetic polymorphism and tailored therapy in hypertension  
[H Zhou]
4. Pharmacogenomics of Human Drug Transporters : From Functional Validation of SNPs to Development of the World-fastest SNP Detection System  
[T Ishikawa]
5. How close are we to the personalized pharmacotherapy?  
[JG Shin]

**S10 : Herbal Medicine Development : Bedside to Bench Top**  
[CT Che/N Bunyapraphatsara]

1. Research and Development of Chili and Chili Products – From Market to Laboratory  
[N Bunyapraphatsara]
2. Meeting the Challenges of Studying Chinese Medicine – Quality Pharmacology, and Clinical Issues  
[CT Che]
3. Importance of Standardization in Botanical Drug Development in Korea  
[J Kim]
4. Natural Products as Lead Compounds in Drug Discovery  
[JW Chern]
5. TCM Modernization: the current status and future perspectives  
[De-an Guo]